Company profile: Hawaii Biotech
1.1 - Company Overview
Company description
- Provider of biotechnology solutions focused on R&D of prophylactic vaccines for infectious diseases, including recombinant subunit vaccines (dengue, West Nile, Zika, tick-borne flaviviruses), viral hemorrhagic fevers (Crimean-Congo), and coronaviruses (SARS-CoV-2, pan-beta). Offers the GPI-0100 adjuvant, a protein production platform for vaccine development, and small molecule therapeutics for anthrax intoxication and botulism (BoNT type A).
Products and services
- Coronavirus Vaccines: Architects prophylactic vaccines for SARS-CoV-2 and other coronaviruses, including a pan-beta coronavirus vaccine candidate
- Recombinant Subunit Vaccines: Engineers prophylactic vaccines using insect cell-derived recombinant proteins produced in stable insect cell lines to target dengue, West Nile, Zika, and tick-borne flaviviruses
- Viral Hemorrhagic Fever Vaccines: Constructs prophylactic vaccines for diseases like Crimean-Congo hemorrhagic fever using proprietary platform-based development targeting viral hemorrhagic fever pathogens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Hawaii Biotech
Alligator Bioscience
HQ: Sweden
Website
- Description: Provider of antibody-based immunotherapies for cancer, including next-generation CD40 agonists and bispecific CD40-targeting antibodies, developed using its FIND® (Fragment INduced Diversity) protein optimization technology, and discovering and developing drug candidates up to phase IIa clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alligator Bioscience company profile →
Arcus Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical cancer therapies, focused on discovering, developing, and commercializing novel treatments. Investigational portfolio includes domvanalimab (Fc-silent anti-TIGIT), zimberelimab (anti-PD-1), etrumadenant (dual A2a/A2b antagonist), quemliclustat (CD73 inhibitor), casdatifan (HIF-2⍺ inhibitor for renal cell cancer), and AB598 (Fc-silent anti-CD39).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcus Biosciences company profile →
Y-mAbs Therapeutics
HQ: United States
Website
- Description: Provider of innovative cancer treatments and support services, including FDA-approved DANYELZA (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma in bone or bone marrow; clinical trials for investigational therapies (naxitamab, omburtamab, GD2-SADA); expanded access programs; Y-mAbs Connect for access, insurance and financial support; and patient and family resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Y-mAbs Therapeutics company profile →
Enumeral Biomedical
HQ: United States
Website
- Description: Provider of a nanotechnology-enabled process for therapeutic discovery, immune profiling, and personalized medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enumeral Biomedical company profile →
InDex Pharmaceuticals
HQ: Sweden
Website
- Description: Provider of clinical-stage biopharmaceutical immunotherapy R&D based on a toll-like receptor (TLR) platform, discovering and developing DNA-based immunomodulatory sequence (DIMS) drugs to treat diseases in therapeutic areas including inflammation and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InDex Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Hawaii Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Hawaii Biotech
2.2 - Growth funds investing in similar companies to Hawaii Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Hawaii Biotech
4.2 - Public trading comparable groups for Hawaii Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →